Contribute Try STAT+ Today

WASHINGTON — Congressional Democrats forced executives from Amgen, Novartis, and Mallinckrodt to explain their price hikes and compensation packages, during a second day of testimony in a series of hearings about their 18-month investigation into pricing practices.

The House Oversight Committee hearing, which followed a Wednesday grilling of executives from Celgene, Bristol Myers Squibb, and Teva Pharmaceuticals, was nearly as meandering as the first. But it was also punctuated with moments of embarrassment and pointed questions for the executives.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.